|
시장보고서
상품코드
2084853
중추성 성조숙증 시장 : 약제별, 유통 채널별, 지역별Central Precocious Puberty Market, By Drug, By Distribution Channel, By Geography |
||||||
중추성 성조숙증 시장은 2026년에 21억 6,470만 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 36억 8,540만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 7.9%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 21억 6,470만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 7.90% | 2033년 시장 규모 예측 : | 36억 8,540만 달러 |
고나도트로핀 방출 호르몬(GnRH) 작용제는 내인성 GnRH의 자극 작용을 억제하고 뼈의 성숙을 촉진함으로써 조기 사춘기를 억제하므로, CPP의 잠재적인 치료 옵션이 됩니다. GnRH 요법은 사춘기 시작을 늦추며, 이로 인해 초경이 지연됩니다. 트립토돌(트립토렐린), 루프론 데포 페도(류프로리드 아세테이트), 그리고 서프레린 LA(히스트렐린 아세테이트)는 중추성 성조숙증(CPP)에 대해 시중에서 구할 수 있는 승인된 치료제입니다. 또한 트립토두르, 루프론 데포 페도 및 사프레린 LA는 필요에 따라 성선 자극 호르몬 분비 억제를 장기화하기 위해 사용되는 성선 자극 호르몬 방출 호르몬(GnRH) 작용제입니다. GnRH 작용제인 트립토렐린은 CPP를 앓고 있는 소아 환자에서 뇌하수체-생식선 축 및 사춘기 발달을 효과적으로 억제합니다.
시장 역학
중추성 성조숙증 치료에 대한 보험 급여는 메디케이드를 통해 이루어지고 있으며, 이는 예측 기간 중 전 세계 중추성 성조숙증 시장에 유망한 성장 기회를 가져다줄 것으로 전망됩니다. 2017년 12월호 N.C. 메디케이드 공보에 따르면 근육내 투여용 서방형 주사용 현탁액인 트립토듀어는 메디케이드의 의료 서비스 공통 절차 코드 체계(HCPCS) 코드 J3490에 따라 적용되고 있습니다. 같은 정보원에 따르면 2017년 9월부터 노스캐롤라이나주 메디케이드 및 노스캐롤라이나 헬스 초이스(NCHC) 프로그램은 의사용 의약품 프로그램(PDP)에서 사용하기 위한 트립토렐린 서방형 근육 주사용 현탁액(트립토듀어)을 급여 대상으로 포함하고 있습니다. 메디케이드 및 NCHC에 대한 청구 시, '트리프토듀아' 1키트당 최대 환급액은 1만 7,280달러입니다.
본 조사의 주요 특징
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하는 한편, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 지역별 전망, 그리고 주요 기업이 채택하고 있는 경쟁 전략에 관한 중요 인사이트도 제공하고 있습니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 재무 실적, 제품 포트폴리오, 사업 전개 지역, 유통 전략, 주요 발전 및 전략, 그리고 향후 계획)를 바탕으로, 전 세계 중추성 성조숙증 시장의 주요 기업 개요을 소개하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 기술 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 이 '세계의 중추성 성조숙증 시장' 보고서는 투자자, 공급업체, 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 중추성 성조숙증 발병 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 중추성 성조숙증 시장 : 약물별, 2021-2033년
제5장 세계의 중추성 성조숙증 시장 : 유통 채널별, 2021-2033년
제6장 세계의 중추성 성조숙증 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 섹션
KSA 26.07.14Central Precocious Puberty Market is estimated to be valued at USD 2,164.7 Mn in 2026 and is expected to reach USD 3,685.4 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.9% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2,164.7 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.90% | 2033 Value Projection: | USD 3,685.4 Mn |
Gonadotropin-releasing hormone (GnRH) agonist are potential treatment options for the CPP as they inhibit stimulation effects of endogenous GnRH and accelerate bone maturation, thereby suppressing early puberty. GnRH therapy delays the onset of puberty leading to delay in menarche Triptodor (triptorelin), Lupron Depot-Ped (leuprolide acetate), and Supprelin LA (histrelin acetate) are approved treatment medications available in the market for central precocious puberty (CPP). Moreover, Triptodur, Lupron Depot-Ped, and Supprelin LA are Gonadotropin-releasing hormone (GnRH) agonists used to prolong the suppression of gonadotropin secretion when required. Triptorelin, a GnRH agonist, effectively suppresses the pituitary-gonadal axis and pubertal development in children with CPP.
Market Dynamics
Reimbursement for the treatment of central precocious puberty is provided through Medicaid, which is expected to offer lucrative growth opportunities for the global central precocious puberty market during the forecast period. According to N.C. Medicaid Bulletin December 2017, Triptodur: an extended-release injectable suspension for intramuscular use, operates under Medicaid Healthcare Common Procedure Coding System (HCPCS) code J3490. According to the same source, from September 2017, N.C. Medicaid and N.C. Health Choice (NCHC) programs cover triptorelin extended-release injectable suspension for intramuscular use (Triptodur) for use in the Physician's Drug Program (PDP). For Medicaid and NCHC billing, the maximum reimbursement rate per unit of Triptodur is: US$ 17,280.00 per kit.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains an attractive investment proposition matrix for this marke
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global central precocious puberty market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., AbbVie Inc., Arbor Pharmaceuticals, LLC, Pfizer Inc., Tolmar Pharmaceuticals, Inc., Endo International plc, Ipsen Pharma, Debiopharm Group, and Sun Pharmaceutical Industries Limited
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global central precocious puberty market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global central precocious puberty market
Market Segmentation
- By Drug (Revenue, USD Mn, 2021-2033)
- Leuprolide Acetate
- Triptorelin
- Histrelin Acetate
- Nafarelin
- By Distribution Channel (Revenue, USD Mn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Central Precocious Puberty Market, By Region (Revenue, USD Mn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Teva Pharmaceutical Industries Ltd.
- AbbVie Inc.
- Arbor Pharmaceuticals, LLC
- Pfizer Inc.
- Tolmar Pharmaceuticals, Inc.
- Endo International plc
- Ipsen Pharma
- Debiopharm Group
- Sun Pharmaceutical Industries Limited
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Global Central Precocious Puberty Market, By Drug, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Leuprolide Acetate
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Triptorelin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Histrelin Acetate
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Nafarelin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Central Precocious Puberty Market, By Distribution Channel, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Central Precocious Puberty Market, By Region, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Arbor Pharmaceuticals, LLC
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Tolmar Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Endo International plc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Ipsen Pharma
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Debiopharm Group
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Sun Pharmaceutical Industries Limited
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Analyst Views
8. Section
- References
- Research Methodology
- About Us
